Ocular Therapeutix (NASDAQ:OCUL) reports sales below analyst estimates in Q3 2026 earnings, stock drops
Ocular Therapeutix (OCUL) reported Q3 2026 revenue of $12.87M, down 11.5% YoY and below estimates. GAAP loss per share was $0.42, missing expectations. Operating margin worsened to -760%. The company's long-term revenue growth has been mediocre, and profitability concerns persist. Analysts expect 50.2% revenue growth over the next 12 months. The stock dropped 7.4% post-earnings.
How this was made

The 30-second read
Why it matters
The earnings miss is the primary catalyst for the stock move; no other major events are mentioned.
Market read
Earnings surprise creates short-term trading opportunity; broader sector may see similar pressure.
What to watch
Analysts expect 50% revenue growth over next 12 months, suggesting potential upside if guidance holds.
Background
Ocular Therapeutix reported Q3 2026 results with revenue and EPS below consensus, leading to a share decline.
Ticker impact
Q3 2026 earnings miss: revenue $12.87M vs $13.92M estimate and EPS -$0.42 vs -$0.36, shares down 7.4% after report.
likely further downside as market prices in revenue and EPS shortfall
The miss was disclosed for the first time and caused a 7.4% drop; traders can act on the negative surprise.
Market effects
Highlights weakness in ophthalmology biotech earnings, may pressure peer stocks.
Limited to US-listed biotech investors.
Minimal; primarily affects niche biotech segment.
Counterpoint
If the company can accelerate product rollout, the miss may be temporary and present a buying opportunity.
Key entities
- CompanyOcular Therapeutix
NASDAQ-listed ophthalmology biopharma.




